<p>IQVIA（纽约证券交易所代码：IQV - 获取免费报告）在周四更新了其 2026 财年的收益指引。该公司提供的每股收益（EPS）指引为 12.550-12.850，而市场共识预期为 12.480。该公司发布的收入指引为 172 亿美元至 174 亿美元，而市场共识收入预期为 171 亿美元。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>超越生物科技——3 只适合成长型投资者的医疗股</li>
</ul>
<p>几位股票分析师最近对 IQV 的股票发表了评论。巴克莱在 12 月 15 日的研究报告中将 IQVIA 的目标价设定为 230.00 美元。汇丰全球研究在 10 月 9 日的研究报告中将 IQVIA 的评级从 “持有” 上调至 “强力买入”。TD Cowen 在 1 月 22 日的研究报告中将 IQVIA 的目标价从 215.00 美元上调至 245.00 美元，并给予该股票 “持有” 评级。Evercore ISI 在 10 月 8 日的报告中将 IQVIA 的目标价从 220.00 美元上调至 240.00 美元，并给予该股票 “跑赢大盘” 评级。最后，摩根大通在 10 月 29 日的报告中将 IQVIA 的目标价从 177.00 美元上调至 255.00 美元，并给予该公司 “增持” 评级。两位分析师给予该股票 “强力买入” 评级，十二位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 251.06 美元。</p>
<p><strong>查看我们关于 IQVIA 的最新研究报告</strong></p>
<h2>IQVIA 股价下跌 0.6%</h2>
<p>纽约证券交易所：IQV 周四开盘价为 202.56 美元。该公司的市值为 345 亿美元，市盈率为 27.79，市盈率/增长比率为 2.07，贝塔值为 1.37。该公司的速动比率为 0.70，流动比率为 0.70，债务与股本比率为 2.03。该公司的 50 日移动平均线为 229.85 美元，200 日移动平均线为 209.62 美元。IQVIA 的 52 周低点为 134.65 美元，52 周高点为 247.04 美元。</p>
<p>IQVIA（纽约证券交易所代码：IQV - 获取免费报告）最近在 2 月 5 日公布了季度收益结果。这家医疗研究公司报告的每股收益（EPS）为 3.42 美元，超出分析师的共识预期 3.40 美元 0.02 美元。IQVIA 的净利润率为 8.07%，股本回报率为 30.70%。该公司的收入较去年同期增长了 10.3%。去年同期，该公司发布的每股收益为 3.12 美元。IQVIA 已将其 2026 财年的指引设定为每股收益 12.550-12.850 美元。研究分析师平均预测 IQVIA 在当前年度的每股收益为 10.84 美元。</p>
<h2>对 IQVIA 的对冲基金观点</h2>
<p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。私人顾问集团在第三季度将其在 IQVIA 的持股增加了 1.0%。私人顾问集团目前拥有 6122 股该医疗研究公司的股票，价值 116.3 万美元，此前在上个季度增持了 63 股。E Fund Management Co. Ltd.在第二季度将其在 IQVIA 的持仓增加了 3.7%。E Fund Management Co. Ltd.目前拥有 2099 股该医疗研究公司的股票，价值 33.1 万美元，此前在该期间增持了 74 股。Ancora Advisors LLC 在第三季度将其在 IQVIA 的持股增加了 17.9%。Ancora Advisors LLC 目前拥有 521 股该医疗研究公司的股票，价值 9.9 万美元，此前在上个季度增持了 79 股。Quadrant Capital Group LLC 在第三季度将其在 IQVIA 的持仓增加了 1.7%。Quadrant Capital Group LLC 目前拥有 4732 股该医疗研究公司的股票，价值 89.9 万美元，此前在该期间增持了 81 股。最后，Snowden Capital Advisors LLC 在第二季度将其在 IQVIA 的持股增加了 5.3%。Snowden Capital Advisors LLC 目前拥有 2364 股该医疗研究公司的股票，价值 37.3 万美元，此前在上个季度增持了 120 股。机构投资者持有该公司 89.62% 的股票。</p>
<h2>IQVIA 公司简介</h2>
<p>（获取免费报告）</p>
<p>IQVIA（纽约证券交易所代码：IQV）是全球领先的生命科学行业高级分析、技术解决方案和合同研究服务提供商。该公司将临床研究能力与大规模健康数据和分析相结合，以支持药物开发、监管报告、商业战略和真实世界证据生成。IQVIA 的当前形式源于 2016 年宣布的 Quintiles 与 IMS Health 的合并，随后重新品牌为 IQVIA，结合了长期建立的临床研究运营和广泛的医疗信息资产。</p>
<p>IQVIA 的主要业务包括外包临床开发服务（作为 I-IV 期的合同研究组织）、真实世界证据和观察性研究、监管和安全服务，以及一系列技术平台，支持数据整合、分析和运营管理。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票超过 IQVIA</li>
<li>黄金市场崩溃的那一天</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>特朗普计划利用公共法 63-43：现在准备好</li>
<li>前 CIA 特工对即将到来的崩溃的看法</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 IQVIA 吗？</h2>
<p>在你考虑 IQVIA 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 IQVIA 并不在名单上。</p>
<p>虽然 IQVIA 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

<p>IQVIA（纽约证券交易所代码：IQV）更新了其 2026 财年的收益指引，预计每股收益在 12.550 到 12.850 之间，超过市场共识预期的 12.480。收入指引设定在 172 亿美元到 174 亿美元，超过市场共识的 171 亿美元。分析师对 IQVIA 的目标价各不相同，巴克莱设定的目标价为 230.00 美元，摩根大通将其上调至 255.00 美元。该股票目前的共识评级为 “适度买入”，目标价为 251.06 美元。IQVIA 的市值为 345 亿美元，最近的交易价格为 202.56 美元</p>

<p>IQVIA (NYSE:IQV - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 12.550-12.850 for the period, compared to the consensus estimate of 12.480. The company issued revenue guidance of $17.2 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion.</p>
<div class="lb-trans"><p>IQVIA（纽约证券交易所代码：IQV - 获取免费报告）在周四更新了其 2026 财年的收益指引。该公司提供的每股收益（EPS）指引为 12.550-12.850，而市场共识预期为 12.480。该公司发布的收入指引为 172 亿美元至 174 亿美元，而市场共识收入预期为 171 亿美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>超越生物科技——3 只适合成长型投资者的医疗股</li>
</ul>
</div><p>Several equities analysts have recently commented on IQV shares. Barclays set a $230.00 price objective on IQVIA in a research report on Monday, December 15th. Hsbc Global Res raised IQVIA from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, October 9th. TD Cowen lifted their price target on shares of IQVIA from $215.00 to $245.00 and gave the stock a &#34;hold&#34; rating in a research note on Thursday, January 22nd. Evercore ISI boosted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, October 8th. Finally, JPMorgan Chase &amp; Co. increased their target price on shares of IQVIA from $177.00 to $255.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $251.06.</p>
<div class="lb-trans"><p>几位股票分析师最近对 IQV 的股票发表了评论。巴克莱在 12 月 15 日的研究报告中将 IQVIA 的目标价设定为 230.00 美元。汇丰全球研究在 10 月 9 日的研究报告中将 IQVIA 的评级从 “持有” 上调至 “强力买入”。TD Cowen 在 1 月 22 日的研究报告中将 IQVIA 的目标价从 215.00 美元上调至 245.00 美元，并给予该股票 “持有” 评级。Evercore ISI 在 10 月 8 日的报告中将 IQVIA 的目标价从 220.00 美元上调至 240.00 美元，并给予该股票 “跑赢大盘” 评级。最后，摩根大通在 10 月 29 日的报告中将 IQVIA 的目标价从 177.00 美元上调至 255.00 美元，并给予该公司 “增持” 评级。两位分析师给予该股票 “强力买入” 评级，十二位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 251.06 美元。</p>
</div><p><strong>View Our Latest Research Report on IQVIA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 IQVIA 的最新研究报告</strong></p>
</div><h2>IQVIA Trading Down 0.6%</h2>
<div class="lb-trans"><h2>IQVIA 股价下跌 0.6%</h2>
</div><p>NYSE:IQV opened at $202.56 on Thursday. The firm has a market capitalization of $34.50 billion, a P/E ratio of 27.79, a P/E/G ratio of 2.07 and a beta of 1.37. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a fifty day moving average of $229.85 and a 200 day moving average of $209.62. IQVIA has a 52 week low of $134.65 and a 52 week high of $247.04.</p>
<div class="lb-trans"><p>纽约证券交易所：IQV 周四开盘价为 202.56 美元。该公司的市值为 345 亿美元，市盈率为 27.79，市盈率/增长比率为 2.07，贝塔值为 1.37。该公司的速动比率为 0.70，流动比率为 0.70，债务与股本比率为 2.03。该公司的 50 日移动平均线为 229.85 美元，200 日移动平均线为 209.62 美元。IQVIA 的 52 周低点为 134.65 美元，52 周高点为 247.04 美元。</p>
</div><p>IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts predict that IQVIA will post 10.84 earnings per share for the current year.</p>
<div class="lb-trans"><p>IQVIA（纽约证券交易所代码：IQV - 获取免费报告）最近在 2 月 5 日公布了季度收益结果。这家医疗研究公司报告的每股收益（EPS）为 3.42 美元，超出分析师的共识预期 3.40 美元 0.02 美元。IQVIA 的净利润率为 8.07%，股本回报率为 30.70%。该公司的收入较去年同期增长了 10.3%。去年同期，该公司发布的每股收益为 3.12 美元。IQVIA 已将其 2026 财年的指引设定为每股收益 12.550-12.850 美元。研究分析师平均预测 IQVIA 在当前年度的每股收益为 10.84 美元。</p>
</div><h2>Hedge Funds Weigh In On IQVIA</h2>
<div class="lb-trans"><h2>对 IQVIA 的对冲基金观点</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC boosted its holdings in IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company's stock valued at $1,163,000 after acquiring an additional 63 shares in the last quarter. E Fund Management Co. Ltd. lifted its position in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company's stock worth $331,000 after purchasing an additional 74 shares during the period. Ancora Advisors LLC boosted its stake in shares of IQVIA by 17.9% during the 3rd quarter. Ancora Advisors LLC now owns 521 shares of the medical research company's stock valued at $99,000 after purchasing an additional 79 shares in the last quarter. Quadrant Capital Group LLC increased its position in shares of IQVIA by 1.7% during the third quarter. Quadrant Capital Group LLC now owns 4,732 shares of the medical research company's stock valued at $899,000 after buying an additional 81 shares during the period. Finally, Snowden Capital Advisors LLC raised its stake in IQVIA by 5.3% in the second quarter. Snowden Capital Advisors LLC now owns 2,364 shares of the medical research company's stock worth $373,000 after buying an additional 120 shares in the last quarter. Institutional investors own 89.62% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。私人顾问集团在第三季度将其在 IQVIA 的持股增加了 1.0%。私人顾问集团目前拥有 6122 股该医疗研究公司的股票，价值 116.3 万美元，此前在上个季度增持了 63 股。E Fund Management Co. Ltd.在第二季度将其在 IQVIA 的持仓增加了 3.7%。E Fund Management Co. Ltd.目前拥有 2099 股该医疗研究公司的股票，价值 33.1 万美元，此前在该期间增持了 74 股。Ancora Advisors LLC 在第三季度将其在 IQVIA 的持股增加了 17.9%。Ancora Advisors LLC 目前拥有 521 股该医疗研究公司的股票，价值 9.9 万美元，此前在上个季度增持了 79 股。Quadrant Capital Group LLC 在第三季度将其在 IQVIA 的持仓增加了 1.7%。Quadrant Capital Group LLC 目前拥有 4732 股该医疗研究公司的股票，价值 89.9 万美元，此前在该期间增持了 81 股。最后，Snowden Capital Advisors LLC 在第二季度将其在 IQVIA 的持股增加了 5.3%。Snowden Capital Advisors LLC 目前拥有 2364 股该医疗研究公司的股票，价值 37.3 万美元，此前在上个季度增持了 120 股。机构投资者持有该公司 89.62% 的股票。</p>
</div><h2>IQVIA Company Profile</h2>
<div class="lb-trans"><h2>IQVIA 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.</p>
<div class="lb-trans"><p>IQVIA（纽约证券交易所代码：IQV）是全球领先的生命科学行业高级分析、技术解决方案和合同研究服务提供商。该公司将临床研究能力与大规模健康数据和分析相结合，以支持药物开发、监管报告、商业战略和真实世界证据生成。IQVIA 的当前形式源于 2016 年宣布的 Quintiles 与 IMS Health 的合并，随后重新品牌为 IQVIA，结合了长期建立的临床研究运营和广泛的医疗信息资产。</p>
</div><p>IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.</p>
<div class="lb-trans"><p>IQVIA 的主要业务包括外包临床开发服务（作为 I-IV 期的合同研究组织）、真实世界证据和观察性研究、监管和安全服务，以及一系列技术平台，支持数据整合、分析和运营管理。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than IQVIA</li>
<li>The day the gold market broke</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Trump Planning to Use Public Law 63-43: Prepare Now</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 IQVIA</li>
<li>黄金市场崩溃的那一天</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>特朗普计划利用公共法 63-43：现在准备好</li>
<li>前 CIA 特工对即将到来的崩溃的看法</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=IQV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in IQVIA Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 IQVIA 吗？</h2>
</div><p>Before you consider IQVIA, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 IQVIA 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 IQVIA 并不在名单上。</p>
</div><p>While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 IQVIA 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

IQVIA（NYSE 代码：IQV）更新了 2026 财年的盈利指引